Preclinical studies of targeted α therapy for breast cancer using (213)Bi-labelled-plasminogen activator inhibitor type 2

The control of micrometastatic breast cancer remains problematic. To this end, we are developing a new adjuvant therapy based on (213)Bi-PAI2, in which an α-emitting nuclide ((213)Bi) is chelated to the plasminogen activator inhibitor-2 (PAI2). PAI2 targets the cell-surface receptor bound urokinase...

Descripción completa

Detalles Bibliográficos
Autores principales: Allen, B J, Tian, Z, Rizvi, S M A, Li, Y, Ranson, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377077/
https://www.ncbi.nlm.nih.gov/pubmed/12644835
http://dx.doi.org/10.1038/sj.bjc.6600838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2377077/
https://www.ncbi.nlm.nih.gov/pubmed/12644835
http://dx.doi.org/10.1038/sj.bjc.6600838

Ejemplares similares